Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib in IgM-associated AL Amyloidosis
NCT02590588Phase 2Terminated
- Start
- Jan 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idelalisib in amyloid light chain amyloidosis. Primary endpoint: Overall Response at 3 months. Started Jan 2016; status: terminated.
02
Drugs
idelalisib
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT02590588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02590588.